|

rTMS for Apathy Clinical Trial

RECRUITINGN/ASponsored by Sunnybrook Health Sciences Centre
Actively Recruiting
PhaseN/A
SponsorSunnybrook Health Sciences Centre
Started2023-02-09
Est. completion2025-12-01
Eligibility
Healthy vol.Accepted

Summary

Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* mild or major neurocognitive disorder OR mild behavioural impairment
* Apathy for at least 4 weeks
* Stable dose of medication (\>4 weeks) that may affect cognition or behaviour
* Care partner who spends at least 10 hours a week with the subject

Exclusion Criteria:

* Current major depressive episode
* Agitation, delusions, hallucination
* Medical contraindications to rTMS
* Currently taking an amphetamine product
* Central nervous system abnormalities, Tourette's syndrome, or motor tics
* Current participation in another clinical trial

Conditions7

Alzheimer DiseaseAlzheimer's DiseaseApathy in DementiaDementiaMild Behavioural ImpairmentMild Cognitive ImpairmentNeurocognitive Disorders

Interventions1

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.